An international team screened 66 natural metabolites and identified apigenin as a senomorphic flavonoid that suppresses the pro-inflammatory secretory phenotype of senescent cells by binding to PRDX6 and modulating HSPA8 activity. In cell and mouse models, apigenin reduced SASP factors, enhanced chemotherapeutic cytotoxicity, and improved physical and cognitive markers in prematurely aged mice.

Key points

• Apigenin binds PRDX6 to inhibit PLA2 activity, reducing arachidonic acid-mediated pro-inflammatory signaling.
• Disruption of HSPA8 interaction attenuates ATM–p38MAPK and PI3K/Akt/mTOR pathways, suppressing SASP factor secretion in senescent cells.
• In murine xenograft and irradiation-induced aging models, apigenin enhances chemotherapeutic apoptosis, reduces tumor burden, and reverses age-related functional decline.

Why it matters: By inhibiting PRDX6-driven SASP, apigenin offers a novel senotherapeutic strategy that enhances chemotherapy efficacy and mitigates age-related decline.

A team led by geneticists at the University of Bath and the National University of Mexico analyzes genome data from 46 mammalian species, uncovering that gene duplication events in immune-related families correlate with both increased maximum lifespan and larger brain volumes. By comparing gene family sizes across species with high-quality genome assemblies, they identify expansions in DNA repair and inflammatory gene clusters that may underlie enhanced tissue maintenance and neural development in long-lived mammals.

Key points

• Comparative genomics of 46 mammalian species with ≥80% genome completeness identifies correlations between gene family size and lifespan metrics.
• Expanded gene families include DNA repair genes (e.g., p53 pathway components) and proinflammatory cytokines (notably interleukin-6), implicating dosage effects.
• Phylogenetic regression analysis links gene duplication rates in immunity clusters with maximum lifespan and brain size, controlling for genome quality and evolutionary relatedness.

Why it matters: Linking immune gene duplications to longevity and brain size reveals potential targets for anti-aging therapies and insights into neural maintenance.

Biotech companies and research teams at Harvard and Columbia University are advancing longevity medicine through senolytic compounds and epigenetic reprogramming, targeting aged cells to potentially reverse cellular damage. Using clinical assays—such as blood biomarker profiling and fitness assessments—they evaluate treatment efficacy. However, experts emphasise that fundamental lifestyle factors—nutrition, physical activity and sleep hygiene—remain the cornerstone of effective lifespan and healthspan extension.

Key points

• Senolytic drugs targeting Bcl-2 family proteins eliminate senescent cells in murine models, improving glucose tolerance and physical endurance.
• Epigenetic reprogramming via transient Yamanaka factor expression restores youthful DNA methylation patterns, reducing epigenetic age acceleration in preclinical assays.
• Calorie restriction in the CALERIE trial yields a 2–3% decrease in biological age, as measured by multi-omic biomarker panels and reduced inflammatory cytokines.

Why it matters: Integrating cutting-edge longevity therapies with proven lifestyle interventions could revolutionise preventive healthcare by targeting ageing’s root causes rather than treating disease.

Montana’s new legislation, championed by longevity enthusiasts and policymakers, allows licensed medical clinics to administer and sell unapproved anti-aging therapies that have completed only phase I clinical trials, expanding right-to-try beyond terminal patients. The law creates an annual licensing framework, informed consent requirements, and protections for prescribing physicians to foster a domestic hub for experimental longevity research and medical tourism.

Key points

• Permits licensed clinics to sell senolytic and gene therapies post-phase I trials without full FDA approval
• Introduces annual licensing, enhanced informed consent, and legal protections for providers under expanded Right to Try provisions
• Requires in-state drug manufacturing, profit-sharing for local healthcare, and aims to establish Montana as a medical tourism hub

Why it matters: This law shifts drug-approval norms by granting early patient access to experimental anti-aging therapies, potentially accelerating longevity research.

A team at Leibniz University Hannover develops a convolutional neural network to predict bandgap width and mid-frequency from binary unit-cell images, then employs a conditional variational autoencoder to generate new unit-cell topologies matching target bandgap properties.

Key points

• CNN with six convolutional layers and two fully connected layers predicts bandgap width and mid-frequency with R²>0.997
• cVAE uses a 20-dimensional latent space and conditional bandgap input to generate 33×33 binary unit-cell topologies with mean MSE≈0.0147
• Combined framework addresses both deterministic forward prediction and probabilistic inverse design for scalable metamaterial development

Why it matters: This AI-driven framework accelerates metamaterial discovery and scalable wave-control design, outperforming trial-and-error methods.

Grand View Research’s report projects the global AI in diagnostics market will expand to USD 5.44 billion by 2030 at a 22.46% CAGR. It evaluates AI-driven software, hardware, and services in radiology and pathology, highlighting drivers such as chronic disease prevalence, workforce shortages, startup funding, and technological advancements.

Key points

• Global AI diagnostics market is forecast to reach USD 5.44 billion by 2030 with a 22.46% CAGR.
• Software solutions dominate with 45.81% revenue share and are expected to grow fastest.
• North America leads with 54.74% market share, with significant growth potential in Asia Pacific.

US legislators insert language into the Budget Reconciliation bill prohibiting state or local AI regulations for ten years, carving out limited exceptions to streamline AI deployment and maintain uniform federal oversight.

Key points

• Congress adds ten-year ban on state enforcement of AI regulations via Budget Reconciliation bill amendment.
• Clause includes carve-outs for laws that facilitate AI deployment, streamline procedures, or impose only reasonable fees.
• State mandates like California’s healthcare AI disclosure rules are preempted unless adopted federally or applied universally.

Why it matters: Centralizing AI oversight limits diverse state protections and shapes a uniform national regulatory framework.

Apple partners with neurotechnology startup Synchron to integrate the Stentrode implant into its Switch Control accessibility framework, enabling direct device control via neural signals in a semi-invasive brain-computer interface.

Key points

• Apple extends its Switch Control framework to support Synchron’s implantable Stentrode BCI.
• Synchron’s Stentrode uses endovascular electrodes to capture cortical signals for device control.
• Meta’s Brain2Qwerty non-invasive model decodes EEG/MEG signals with 19% character error rate.

Why it matters: Integrating BCI into mainstream devices democratizes access for motor-impaired users and accelerates broader adoption of neural interfaces across industries.

Engineers at leading technology companies integrate artificial intelligence with machine learning by deploying advanced neural network architectures that analyze extensive datasets, enabling continuous model refinement and accurate predictive analytics across domains such as personalized media recommendations and early disease detection.

Key points

• Deep neural networks automate feature extraction from large datasets, reducing manual labeling time by over 50%.
• Real-time adaptive learning algorithms continuously update predictive models using incoming data streams.
• Personalized recommendation engines and diagnostic models achieve up to 90% accuracy in user preference and anomaly detection.

Why it matters: By combining AI with machine learning, businesses and healthcare providers can unlock faster, more accurate predictions, driving innovation across multiple sectors.

ResearchAndMarkets' latest Business Intelligence Report reveals that the global generative AI in logistics market is projected to grow from $1.3B in 2024 to $7.0B by 2030 at a 32.5% CAGR. The report details how predictive analytics, IoT integration, and AI-driven automation transform routing, warehouse operations, and customs workflows, enabling providers to reduce operational costs, enhance supply chain visibility, and personalize last-mile delivery services in key regional markets.

Key points

• Market projected to expand from $1.3B in 2024 to $7.0B by 2030 at a 32.5% CAGR
• AI-driven route optimization uses real-time traffic, weather, and fuel data to reduce transit times and emissions
• Predictive maintenance via IoT sensors and historical analytics minimizes equipment downtime and maintenance costs

The Department of Computer Engineering at Jamia Millia Islamia launches a three-week Short Term Training Programme on Artificial Intelligence and Machine Learning. Scheduled in hybrid mode, the 50-hour curriculum combines 20 hours of theoretical lectures and 30 hours of practical sessions, spanning modules such as Python programming, applied data science, machine learning algorithms, and deep learning frameworks like Keras and TensorFlow. It aims to equip diploma, undergraduate, postgraduate, and Ph.D. candidates with industry-relevant AI skills.

Key points

• 50-hour hybrid programme split into 20 hours of theory and 30 hours of practical training
• Curriculum covers AI & Python basics, applied data science, ML algorithms, and deep learning for vision and NLP
• 160 seats available: 60 offline and 100 online on a first-come, first-served basis

Why it matters: This STTP cultivates a skilled AI workforce by blending theory and hands-on practice, addressing talent gaps and driving applied innovation.